Valerio Toyos-Olascoaga, MD
Internal Medicine · Miami, FLNPI 1912196973
Payments from drug & device makers
Across 56 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$190
- GSK$180
- Novo Nordisk$115
- Ironwood Pharmaceuticals, Inc$114
- AbbVie$108
- AstraZeneca$78
- plus $234 from 12 others
What the payments were for
- Food & beverage$1,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $190 |
| GSK | 11 | $180 |
| Novo Nordisk | 7 | $115 |
| Ironwood Pharmaceuticals, Inc | 1 | $114 |
| AbbVie(2 entities) | 6 | $108 |
| AstraZeneca | 4 | $78 |
| Lilly USA, LLC | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Eisai Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$228
How this compares
$1,020 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $123,288 |
| OzempicSemaglutide | 98 | $108,501 |
| FarxigaDapagliflozin Propanediol | 57 | $66,361 |
| EntrestoSacubitril/Valsartan | 54 | $62,430 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $40,512 |
| XareltoRivaroxaban | 26 | $39,426 |
| JardianceEmpagliflozin | 30 | $37,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $29,064 |
| MounjaroTirzepatide | 19 | $19,986 |
| Tadalafil | 81 | $17,579 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $16,735 |
| LinzessLinaclotide | 26 | $16,101 |
| JubliaEfinaconazole | 14 | $15,181 |
| LumiganBimatoprost | 38 | $13,179 |
| VascepaIcosapent Ethyl | 23 | $9,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $123,288117 claims |
| Novo NordiskOzempic | $115 | $108,50198 claims |
| AstraZenecaFarxiga, Symbicort | $78 | $68,96468 claims |
| NovartisEntresto | $19 | $62,43054 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $45,79980 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $15 | $43,76842 claims |
| Johnson & JohnsonXarelto | $190 | $39,42626 claims |
| AbbVieLinzess, Lumigan, Synthroid | $108 | $35,061113 claims |
| Lilly USA, LLCMounjaro, Humalog Mix 75-25 | $46 | $25,61331 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $14 | $15,18114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Mark KutnerMiami$35.7M
- Mercedes Ponce de LeonMiami$6.8M
- Alejandro de la CruzMiami$6.2M
- Roberto SotolongoMiami$5.8M
- Enrique PelayoMiami$5.4M
- Renato DominguezMiami$5.2M
- Ramses VegaMiami$4.4M
- Dunia Llapur HernandezMiami$4.3M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.